dendritic vaccine + autologous hematopoietic stem cells + cytotoxic lymphocytes

This therapy is a personalized, multi-component cell-based immunotherapy combining three elements: - **Dendritic vaccine**: Dendritic cells (DCs) are generated from the patient's own precursor cells (often monocytes or hematopoietic stem cells), loaded with tumor antigens, and administered to stimulate an anti-tumor immune response by presenting these antigens to T lymphocytes[7][5][2]. - **Autologous hematopoietic stem cells**: These are the patient’s own blood-forming stem cells, typically collected via apheresis after chemotherapy. They may be used for immune system reconstitution following high-dose chemotherapy or as a source for generating dendritic cells[7][1]. - **Cytotoxic lymphocytes**: This refers to T lymphocytes (such as CD8+ cytotoxic T-cells) that can directly kill tumor cells. The therapy aims to expand and activate these tumor-reactive cytotoxic lymphocyte populations in vivo through vaccination and/or adoptive transfer[1][5]. The combination is designed primarily for cancer immunotherapy—most notably in multiple myeloma and other malignancies—where it seeks to induce durable anti-tumor immunity by harnessing both innate and adaptive immune responses. Clinical trials have shown that such approaches can increase circulating tumor-reactive T-cells, improve progression-free survival, and may lead to long-term disease control in some patients[1][5]. The approach remains investigational but has demonstrated safety and immunogenicity in early-phase studies.

Other names

MM-SC-DC vaccineSC-DC vaccine